Skip to content

The Long-term Effect of Tianqi Capsule Interventions to Prevent Diabetes in the REDUCES Study: a 8-year Follow-up Study

The Long-term Effect of Tianqi Capsule Interventions to Prevent Diabetes in the REDUCES Study: a 8-year Follow-up Study

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02848053
Enrollment
420
Registered
2016-07-28
Start date
2016-08-31
Completion date
2016-11-30
Last updated
2016-10-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Impaired Glucose Tolerance, Type 2 Diabetes Mellitus

Brief summary

Objectives: This study is aimed to assess whether Tianqi Capsule interventions have a long-term effect on the risk of diabetes and provide evidence that early intervention by traditional Chinese medicine could delay the progression from impaired glucose tolerance to diabetes. Study contents: 1.420 participants were followed up for 8 years to assess the long-term effect of Tianqi Capsule. Phone-call followed up was applied to investigate the status of impaired glucose tolerance and orthoglycemic survivors until the end of REDUCES study. 2.To participants that determined the status of glucose metabolism, a variety of ways were used to find the evidence of diagnosis of glucose metabolic status, such as glycemia laboratory sheets from normal hospitals, medical records, the use of antidiabetic drugs or insulin injection, etc. 3. To participants that undiagnosed the status of glucose metabolism, oral glucose tolerance test, blood pressure, weight and blood biochemical analysis were performed to assess the state of glucose metabolism. 4. Questionnaires were given to all the participants to investigate their condition of treatment, diet, exercise and other lifestyle.

Detailed description

Study design: Perspective study Study drug: Tianqi CapsuleInclusion criteria: 1. Subjects have participated in the REDUCES study before; 2. Informed consent forms were needed to participants performed to blood test; 3. Laboratory sheets could be voluntary acquirement by participants that determined the status of glucose metabolism; 4.Subjects were not disabled, and could take care of themselves. 5. Subjects did not suffer the infectious disease. Exclusion criteria: 1. Subjects did not participate the REDUCES study; 2. Subjects suffered serious mental illness; 3. Subjects suffered severe mental or cognitive impairment; 4. Subjects had a history of drug or alcohol dependence; 5. Subjects have participated in other drug clinical trials in the past 1 month. Main outcome index: Incidence of diabetes. Secondary outcome index: Body mass index, fasting blood-glucose, postprandial blood sugar, blood lipids, blood pressure.

Interventions

OTHERno intervention

Sponsors

Hubei College of Traditional Chinese Medicine
CollaboratorOTHER
Guang'anmen Hospital of China Academy of Chinese Medical Sciences
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
25 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

* Subjects have participated in the REDUCES study before; * Informed consent forms were needed to participants performed to blood test; * Laboratory sheets could be voluntary acquirement by participants that determined the status of glucose metabolism; * Subjects were not disabled, and could take care of themselves. 5. Subjects did not suffer the infectious disease.

Exclusion criteria

* Subjects did not participate the REDUCES study; * Subjects suffered serious mental illness; * Subjects suffered severe mental or cognitive impairment; * Subjects had a history of drug or alcohol dependence; * Subjects have participated in other drug clinical trials in the past 1 month.

Design outcomes

Primary

MeasureTime frame
Incidence of diabetes0 week

Secondary

MeasureTime frame
Number of participants with abnormal Diastolic Blood Pressure values (in mmHg)0 week
Number of participants with abnormal blood glucose values (in mmol/L)0 week
Number of participants with abnormal High density lipoprotein values (in mmol/L)0 week
Number of participants with abnormal Systolic Blood Pressure values (in mmHg)0 week
Number of participants with abnormal Triglycerides values (in mmol/L)0 week
Number of participants with abnormal Cholesterol values (in mmol/L)0 week
Number of participants with abnormal Low density lipoprotein values (in mmol/L)0 week
Number of participants with abnormal body mass index values (in kg/m^2)0 week

Contacts

Primary ContactFengmei Lian, PHD
lfm565@sohu.com0086-010-88001402

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026